Amylin Pharma (AMLN) Too Expensive
At this time the valuation on Amylin is not attractive. There are few catalysts and operating expenses are soaring.
|
|
|
Share |
RSS |
Rate Pos |
Rate Neg |
Comment |
|
|
||||||
Loading Stories...Most Popular on Zacks.com
More Zacks Resources
More Zacks Links
| Market Summary | Nov 21, 2009 18:18 pm ET |

Sponsored Links 
-2.58 %
[CLICK TO CLOSE X]